Clinical trials: Hair Diseases
Thin Hair, Hair Loss
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth by applying a serum daily on the scalp of men and women with thinning hair. The main aims of this trial are: 1.
- Conditions
- Thin Hair, Hair Loss, Alopecia, Thinning Hair
- Trial name
- NCT07228156
- Testing
- Xtresse Serum
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia, Female Pattern Baldness
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).
- Trial name
- NCT05888922
- Testing
- Minoxidil Tablets, Minoxidil Topical, Vehicle solution
- Where
- 27 sites in Germany, Italy and 2 more
- Volunteers
- 520 people
- Sponsor
- Industrial Farmacéutica Cantabria, S.A.
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study
Alopecia areata (AA) is a common autoimmune disease that targets hair follicles with a prevalence of approximately 0.1% and a lifetime incidence of approximately 1.7%. AA is the third most prevalent nonscarring hair loss disease.
- Trial name
- NCT05502952
- Testing
- Pentoxifylline
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Central Centrifugal Cicatricial Alopecia
Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia
This study aims to investigate whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that mostly affects women of African descent.
- Trial name
- NCT06998433
- Testing
- Platelet-Rich Plasma (PRP) Injections, Saline
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Baylor College of Medicine
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451021
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Autoimmune Diseases, Inflammatory Disease
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system.
- Conditions
- Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia, Systemic Lupus Erythematosus
- Trial name
- MuTreg (NCT05544448)
- Testing
- Blood sample taken at a single time point
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alopecia
LLLT for Alopecia of the Eyebrow in Women
The purpose of this research is to study the ongoing effectiveness of a light therapy device for human hair growth. This device, called the iRestore Eyebrow Device, is a type of cold, or non-heat producing light therapy system…
- Trial name
- NCT04897555
- Testing
- LLLT
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Alopecia
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido.
- Trial name
- NCT02014584
- Testing
- Dutasteride
- Where
- 18 sites in Chile, Hong Kong and 3 more
- Volunteers
- 117 people
- Sponsor
- Stiefel, a GSK Company
Alopecia Areata
Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
Alopecia areata (AA) in the acute phase with active hair shedding causes significant psychological distress, prompting the need for effective treatment.
- Trial name
- MQ7422 (NCT06797310)
- Testing
- Baricitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Androgenic Alopecia
Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia
Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical…
- Trial name
- NCT07502976
- Testing
- Topical 2-Deoxy-D-ribose Hydrogel, Topical Minoxidil 5% Solution
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kasr El Aini Hospital
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Phase II clinical trial
- Trial name
- ELAN (NCT02919735)
- Testing
- CG 428 cutaneous solution
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Legacy Healthcare SA
Alopecia Areata
Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.
- Trial name
- NCT00484679
- Testing
- Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Excessive Hairiness, Vascular Lesion
Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias.
- Conditions
- Excessive Hairiness, Vascular Lesion, Pigmented Lesions, Acne Vulgaris
- Trial name
- Anthelia (NCT06655129)
- Testing
- intense pulsed light
- Where
- 5 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Eurofeedback
Alopecia Areata, Alopecia Totalis
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06278402
- Testing
- Tofacitinib
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Jinnah Hospital
Hypotrichosis
Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow Hypotrichosis
A Prospective, single arm, and interventional Clinical Trial
- Trial name
- NCT07775989
- Testing
- dermo cosmetic product
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Quantum Aesthetics Cosmetics
Androgenetic Alopecia
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
- Trial name
- NCT04945226
- Testing
- Finasteride 1mg Tablet, IVL3001
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AAJP (NCT07617597)
- Testing
- Deuruxolitinib
- Where
- 18 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Sun Pharma Japan Limited
Medication Adherence
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN)
This is a pilot study to assess the feasibility, acceptability and appropriateness of delivery of the investigational "MedViewer" intervention in adult patients living with HIV who have been prescribed antiretroviral (ARV)…
- Trial name
- ENLIGHTEN (NCT04232540)
- Testing
- MedViewer report
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of North Carolina, Chapel Hill